Harrow, Inc. is rapidly evolving into a dominant US ophthalmic pharma player, with a 30-fold revenue increase since 2015 and ...
That gave us an adjusted earnings per share of 6.1p. Our net debt to adjusted EBITDA at 1.4x remains strong and within our guided range of below 1.5x. We had an excellent adjusted operating cash ...
A Lightweight Self-Supervised Representation Learning Framework for Depression Risk Profiling from Synthetic Daily Behavioural Trajectories ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results